WASHINGTON, DC — The Food and Drug Administration has issued an early alert for all automated Impella controllers made by Abiomed after the problem was linked to three deaths and 37 serious injuries as of Aug. 17. The agency said the devices have had purge cassette recognition problems tied to failures in a purge flag component inside the purge pressure sensor assembly.

Abiomed has already sent a letter to affected customers telling them to remove the devices from where they are used or sold. The alert places the problem in the category of a device safety issue that can affect how hospitals and other users respond while the company and regulators work through the details.

What FDA Announced

The FDA said the early alert covers all automated Impella controllers by Abiomed. It identified the issue as a purge cassette recognition failure related to the purge flag component within the purge pressure sensor assembly.

According to the agency, those failures had been associated with three deaths and 37 serious injuries reported through Aug. 17. Abiomed’s customer letter called for the affected devices to be removed from where they are used or sold, which is the immediate step the company has communicated to users and distributors.

How The Problem Emerged

The controller issue surfaced through reports that the devices were experiencing trouble recognizing the purge cassette. The FDA tied that trouble to a specific internal component in the pressure sensor assembly, rather than to the broader heart pump platform as a whole.

Impella controllers are used in settings where teams rely on precise device function, so a failure of this kind can affect hospitals, clinics and any other customer with the affected equipment. The agency’s alert and Abiomed’s letter together indicate that the devices have already reached users nationwide and that the matter has become a post-distribution safety problem.

What Users Should Watch

Anyone responsible for the affected devices should follow the instructions in Abiomed’s letter and check notices from the FDA for updates. The company’s communication says the devices should be removed from where they are used or sold, and the FDA alert provides the public-health context for why the problem matters.

Readers who need the latest official information can monitor the FDA and Abiomed for further actions, including any correction or recall details that may follow. The current alert does not add a new number of devices involved, and it does not say when the issue will be fully resolved.

More on health, care, money and the people nearby, on Westlake Arrow.